Equities researchers at Wells Fargo & Company have reaffirmed an “equal weight” rating for uniQure (NASDAQ: QURE) in a recent research note issued to investors. This rating comes with a revised price target of $15.00, significantly reduced from the previous target of $60.00. The new target indicates a potential upside of 42.86% from the stock’s last closing price.
The shift in valuation reflects broader sentiment within the investment community, as several research firms have recently updated their ratings on uniQure. TD Cowen maintained a “buy” rating, while HC Wainwright also reaffirmed a “buy” rating with a price target of $70.00. Conversely, Stifel Nicolaus has set a lower target of $14.00, and Weiss Ratings downgraded the stock to a “sell (d-)” rating earlier this year. Barclays began coverage with an equal weight rating and a target price of $31.00.
Investor sentiment is mixed, with seven analysts issuing a “buy” rating, nine assigning a “hold” rating, and one recommending a “sell” rating. According to data from MarketBeat.com, uniQure currently holds an average rating of “hold” with a target price of $36.75.
Recent Insider Sales and Market Movements
In related developments, insider trading activity has also raised eyebrows. Jack Kaye, a director at uniQure, sold 6,390 shares on January 9, realizing approximately $174,319.20 at an average price of $27.28. Following this transaction, Kaye’s holdings decreased by 23.82% to 20,439 shares, valued at around $557,575.92.
Another insider, Robert Gut, sold 25,613 shares on January 12, generating a total of approximately $630,592.06 at an average price of $24.62. This sale represented a 44.19% reduction in his ownership, leaving him with 32,342 shares valued at around $796,260.04. In total, insiders sold 50,598 shares over the past 90 days, amounting to a value of $1,248,588. Currently, insiders hold 4.79% of the company’s stock.
Institutional Investors Take Positions
Recent activity among institutional investors has also influenced uniQure’s stock performance. Private Trust Co. NA initiated a new position during the third quarter, valued at approximately $28,000. Meanwhile, Jones Financial Companies Lllp significantly increased its stake by 509.0%, acquiring an additional 509 shares for a total of $33,000.
Other notable changes include China Universal Asset Management Co. Ltd., which raised its position by 5.5%, and Arizona State Retirement System, which increased its holdings by 6.0%. In total, institutional and hedge fund ownership accounts for 78.83% of uniQure’s outstanding shares.
uniQure’s Focus and Pipeline
Founded in 1998, uniQure N.V. specializes in developing gene therapies for serious medical conditions. Utilizing its proprietary adeno-associated viral (AAV) vector platform, the company aims to create single-dose treatments that address the root genetic causes of diseases.
One of its leading products, Hemgenix® (etranacogene dezaparvovec), has gained regulatory approval in both the United States and Europe for treating adult patients with hemophilia B. This marks a significant advancement in the field of gene therapy for bleeding disorders. The company’s pipeline also includes candidates targeting rare conditions like aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
As the market continues to evolve, investors will be closely monitoring uniQure’s performance and any updates from analysts regarding its future prospects.
